Dry Cereals Fortified with Electrolytic Iron or Ferrous Fumarate Are Equally Effective in Breast-fed Infants by Ziegler, Ekhard E. et al.
The Journal of Nutrition
Nutrient Requirements and Optimal Nutrition
Dry Cereals Fortified with Electrolytic Iron or
Ferrous Fumarate Are Equally Effective in
Breast-fed Infants1–3
Ekhard E. Ziegler,4* Samuel J. Fomon,4,7 Steven E. Nelson,4 Janice M. Jeter,4 and Richard C. Theuer5,6
4Fomon Infant Nutrition Unit, Department of Pediatrics, University of Iowa, Iowa City, IA 52242; 5Department of Food, Bioprocessing
and Nutrition Sciences, North Carolina State University, Raleigh, NC 27695; and 6Department of Nutrition, School of Public Health,
University of North Carolina, Chapel Hill, NC 27599
Abstract
Precooked, instant (dry) infant cereals in the US are fortified with electrolytic iron, a source of low reactivity and suspected
low bioavailability. Iron from ferrous fumarate is presumed to be more available. In this study, we compared a dry infant
rice cereal (Cereal L) fortified with electrolytic iron (54.5 mg iron/100 g cereal) to a similar cereal (Cereal M) fortified with
ferrous fumarate (52.2 mg Fe/100 g) for efficacy in maintaining iron status and preventing iron deficiency (ID) in breast-fed
infants. Ascorbic acid was included in both cereals. In this prospective, randomized double-blind trial, exclusively breast-
fed infants were enrolled at 1 mo and iron status was determined periodically. At 4 mo, 3 infants had ID anemia and were
excluded. Ninety-five infants were randomized at 4 mo, and 69 (36 Cereal L, 33 Cereal M) completed the intervention at
9 mo. From 4 to 9 mo, they consumed daily one of the study cereals. With each cereal, 2 infants had mild ID, a prevalence
of 4.2%, but no infant developed ID anemia. There were no differences in iron status between study groups. Iron intake
from the study cereals was (mean 6 SD) 1.21 6 0.31 mg×kg21×d21 from Cereal L and 1.07 6 0.40 mg×kg21×d21 from
Cereal M. Eleven infants had low birth iron endowment (plasma ferritin , 55 mg/L at 2 mo) and 54% of these infants had
ID with or without anemia by 4 mo. We conclude that electrolytic iron and ferrous fumarate were equally efficacious as
fortificants of this infant cereal. J. Nutr. 141: 243–248, 2011.
Introduction
The iron in breast milk is highly bioavailable (1,2), but its
concentration is low [0.2–0.4 mg/L (3.6–7.2 mmol/L)]. There-
fore, once the birth iron endowment is exhausted at ~4–6 mo of
age, the breast-fed infant largely depends on iron from sources
other than breast milk to meet the high iron needs for growth.
The occurrence of iron deficiency (ID)8 in breast-fed infants,
including its severe form, ID anemia (IDA), has been docu-
mented in a number of countries and localities (3–16). Severe ID
at an early age can impair behavioral and neurocognitive
development (17–20), so prevention of ID is important.
Most complementary infant foods contain little natural iron.
Substantial amounts of iron are provided only by meats and
iron-fortified foods, such as infant cereals. The latter are
consumed by the great majority of infants in the US. In 2005–
2007, 83.2% of infants aged 7.5–9 mo consumed infant cereals
(21). Precooked, instant (dry) infant cereals in the US are
fortified with electrolytic iron (A-131), a form of iron of small
particle size but with low chemical reactivity that does not
impart undesirable organoleptic characteristics to precooked
instant cereal products (22). More than 90% by weight of the
particles of A-131 are ,30 mm in diameter and 40% by weight
are ,10 mm (22). The bioavailability of electrolytic iron has
been questioned (23), largely on the basis of the findings of
Elwood et al. (24). However, the particle size distribution of the
electrolytic iron studied was markedly different from that of
A-131 and the conclusion that A-131 is poorly available may not
be justified. Although some studies in adults have shown poor
availability of A-131 (25), others have shown availability as high
as 86% that of ferrous sulfate (26). In the 1 study that examined
the efficacy of A-131 as a fortificant of infant cereal (9), the fact
that the cereal substantially reduced the prevalence of ID in both
breast-fed and formula-fed infants is consistent with at least
moderate efficacy of A-131.
Ferrous fumarate, which is more soluble than electrolytic
iron, is suitable as a fortificant of infant cereals in that it does not
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cause discoloration and does not affect taste (27). The iron from
ferrous fumarate added to a reconstituted dry cereal was only
slightly less available to infants than the iron from ferrous sulfate
in a wet-pack fruit-cereal baby food (28). Dry infant cereal made
with ferrous fumarate was a more efficacious source of iron for
infants than ferrous pyrophosphate when ascorbic acid was
added after reconstitution (29). However, no comparison of the
relative iron status of infants fed cereal fortified with ferrous
fumarate compared with cereal fortified with A-131 electrolytic
iron has been reported.
The present study was designed to compare in breast-fed
infants ferrous fumarate with A-131 electrolytic iron with
regard to efficacy in maintaining iron status and preventing ID
when used as fortificants of dry infant cereal. Measures of
efficacy were maintenance of iron status and protection from ID.
We hypothesized that ferrous fumarate would be more effica-
cious than electrolytic iron. Because infant formula is a source of
iron, infants in the present study were not permitted to receive
formula. Because IDAmay adversely affect mental development,
infants were treated with therapeutic doses of iron when
IDA was discovered at any time during the study, and their
subsequent data were excluded.
Materials and Methods
Study design. This was a randomized, double-blind trial that involved
infants who were exclusively breast-fed during the first 4 mo of life. They
were enrolled at 1 mo and were followed through 12 mo of age. At 4 mo,
infants were randomly assigned to 1 of 2 study cereals (Cereal L or M).
Cereal L was fortified with electrolytic iron and Cereal M was fortified
with ferrous fumarate. To be randomized at 4 mo, infants had to be
exclusively breast-fed, meaning they received no infant formula and no
complementary foods. The infants received the study cereals from 4 to
9 mo (study intervention). A follow-up assessment at 12 mo was included
to determine whether there was a sustained effect of cereal on iron status.
Iron status was assessed at 2, 4, 5.5, 7.5, 9, and 12 mo. Infants who
developed IDA [PF , 10 mg/L and hemoglobin (Hb) , 105 g/L] were
treated with iron and, if IDA occurred by 4 mo, were not randomized.
Infants with ID (PF , 10 mg/L) without anemia were randomized.
Randomization was performed with stratification by gender (males,
females), birth weight (,3500 g, $3500 g), and PF at 2 mo (,150 mg/L,
$150mg/L). Randomizationwas by computer-generated sequence. Infants
returned to the study center every 4 wk for anthropometry and to receive a
new supply of study cereals. Capillary blood was obtained during visits at
2, 4, 5.5, 7.5, 9, and 12 mo.
Participants. We studied term infants of either gender with birth weight
. 2500 g who were considered normal by their physicians and the
investigators. They were born between June 2003 and June 2005. Most
were Caucasian with only 1 being mixed race African American/
Caucasian. They were exclusively breast-fed at the time of enrollment
and the mother intended to breast-feed to 9 mo and did not intend to use
formula. The study team was not involved in providing health care to
study infants. The study protocol was reviewed and approved by the
University of Iowa Institutional Review Board and 1 parent provided
written informed consent.
The flow of study infants is indicated in Figure 1. A total of 111
infants were enrolled at 1 mo of age. Sixteen infants were excluded or
were withdrawn by their parents due to scheduling problems. The
remaining 95 infants were randomized at 4 mo. Fifty infants were
assigned to Cereal L (22 females, 28 males) and 45 to Cereal M (18
females, 27 males). Eight infants did not finish the study because they
refused to take the cereal (3 fed Cereal L, 5 fed Cereal M). Eleven infants
did not finish the study because of their mothers’ insufficient breast milk
supply, which necessitated the feeding of formula, and 7 infants did not
finish for reasons unrelated to the study, mostly scheduling difficulties.
Thus, a total 69 infants (36 Cereal L, 33 Cereal M) completed the
intervention at 9 mo and all of these infants completed the study to
12 mo.
Sample size. For regular feeding of an iron-fortified infant cereal to be
considered a reliable means of preventing ID in breast-fed infants, we
thought that no more than 3% of infants so fed should develop ID. We
based our sample size calculation on the assumption that 20% of breast-
fed infants who do not regularly receive medicinal iron or an iron-
fortified food will become iron deficient at or before 9 mo of age. This
value was taken from the literature (9,10). In a study we had completed
earlier (16) only 17% of infants in the control group developed ID, but in
that study infants were permitted to receive supplemental iron-fortified
formula, which was prohibited in the present study. To demonstrate
efficacy, i.e. ID in #3% of infants, for either of the study cereals, 37
infants per group were needed with a = 0.05 and power of 0.80 (30). We
assumed that 70% of infants enrolled at 1 mo would complete the study
as planned and we therefore planned to enroll 106 infants.
Feedings. Feeding decisions were entirely at the parents’ discretion.
From the time of enrollment, parents were supplied with vitamin drops
that provided each day 0.45 mg (1.57 mmol) retinol acetate, 35 mg
vitamin C, and 10 mg cholecalciferol. Other vitamin supplements were
permitted. However, to remain in the study, infants could not receive
medicinal iron, could not receive any nonstudy cereal, and could not
receive any formula.
The study cereals were produced and provided free of charge by the
Beech-Nut Nutrition Corporation. The cereals were identical in appear-
ance, ingredients, and composition except for the nature of the fortification
iron. The cereals were prepared by cooking an aqueous rice flour slurry
containing the fortification iron and other nutrient additives by steam
injection and drying with a drum dryer. Cereal L was a commercially
available rice cereal fortified with electrolytic iron A-131 and contained
54.5 mg of iron/100 g of dry cereal. CerealMwas a specially prepared rice
cereal fortified with ferrous fumarate that contained 52.2 mg of iron/100 g
of dry cereal. Each serving (15 g) contained 200 mg calcium, 63 mg
FIGURE 1 Flow of infants through the study.
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phosphorus, 2.0 mg zinc, and small amounts of other minerals, 8 water-
soluble vitamins, and tocopherol. Ascorbic acid was included in both
cereals at 250 mg/100 g of total dry ingredients prior to cooking and
drying. The ascorbic acid level was,10% of the originally added amount
15 mo after production and ,2% of the original amount 50 mo after
production, which was 1 y after the final feeding.
The study cereals were fed from 4 to 9 mo of age. They were packaged
in identical code-labeled cartons. Mothers were instructed to reconstitute
the cereal with expressed breastmilk, water, or juice, but not with formula.
When infants were between 112 and 140 d of age, parents could feed any
amount of study cereal. This was done to accommodate the usual parental
preference for initially feeding small amounts of complementary foods.
When infants were 140 d of age and continuing through 280 d, the parents
were requested to feed ;15 g (dry weight) of the study cereal daily,
equivalent to 70 g of prepared cereal porridge (i.e. aftermixing with liquid)
and providing ;8 mg of iron. The amount of study cereal actually
consumed was estimated as the difference in weight by weighing cereal
containers before dispensing and weighing back returned empty and
partially used containers at the next visit.
Procedures. Infants visited the Fomon Infant Nutrition Unit every 28 d
up to 9 mo of age and again at 12 mo. Study visits occurred with very few
exceptions within 4 d of the designated age. At each visit, weight and
length were measured using established methods (31). Before each visit,
parents completed a feeding questionnaire that asked whether the infant
was fed formula and/or complementary foods and howmuch of these the
infant typically consumed. The questionnaires were checked during visits
for completeness by the nursing staff and any ambiguities were clarified.
Blood was obtained at 2 mo (56 d), 4 mo (112 d), 5.5 mo (168 d), 7.5 mo
(224 d), 9 mo (280 d), and 12 mo.
Blood collection and analysis. Capillary blood was collected by heel
stick using a disposable spring-loaded device (Tenderfoot, International
Technidyne). Approximately 1 mL of blood was collected into a heparin-
treated tube. The Hb concentration and RBC indices (mean corpuscular
volume, relative distribution width) were determined immediately on
whole blood using a Coulter AcT diff Hematology Analyzer (Coulter).
The blood was then centrifuged and plasma was used for the other
measurements. Ferritin was measured (initial ;20% of determinations)
by RIA using the Quantimune kit (Bio-Rad Laboratories). After the
Quantimune kit was withdrawn from the market, ferritin was measured
using an immunoradiometric procedure (Ramco catalog no. F-11). The
interassay CVwas 18.4%. Quantimune values were converted to Ramco
values by multiplying by 0.739. Soluble transferrin receptor (sTfR) was
measured by enzyme immunoassay using the Ramco kit (catalog no.
TF-94). Iron was determined by a colorimetric method using ferrozine as
the chromogenic substrate. C-reactive protein (CRP) was determined by
a 2-sided ELISA developed in our laboratory (16).
Data analysis. ID was defined as PF, 10 mg/L and anemia was defined
as Hb , 105 g/L before 9 mo and as Hb , 100 g/L at 9 mo and older
(32). Although a ferritin cutoff of 12 mg/L is widely used, we prefer the
more conservative cutoff of 10mg/L (33), which indicates absence of iron
stores. Data for the 5 infants (Table 2) whowere not randomized because
of poor iron status were not included in the data analysis. Data for
infants who left the study were included up to the point of departure and
data for infants who were excluded because of supplemental formula
feeding (i.e. mothers’ insufficient breast milk supply) were included up to
the visit preceding the one where formula consumption was reported. A
separate analysis was performed restricted to data for the 69 infants who
completed the study to 12 mo (per protocol analysis).
Because ferritin is an acute-phase reactant, during inflammation or
infection PF may be elevated and not reflective of iron stores. The
presence of ID can thus be masked and the size of iron stores
overestimated. Unfortunately, concurrent measurement of plasma CRP
is not a reliable means of identifying PF values that are acute-phase
elevated. From our longitudinal data, it is evident that PF may sometimes
be normal in the presence of elevated CRP and, conversely, PF may be
clearly elevated when CRP is normal. We presume that these circum-
stances reflect a lack of concurrence between the timing of increase and
subsequent decrease of the 2 acute phase reactants (CRP and PF). We
have therefore classified a PF value as elevated if it is 3-fold greater than
the mean of the preceding and subsequent values. The classification of
elevated PF values therefore rested entirely on 2 adjacent PF values and
was not influenced by CRP. The classification was not applied to values
at 56 d. Two PF values were identified in this fashion as elevated and
were excluded from data analysis.
Indicators of iron status were compared between study groups by t
tests and 2-factor (group, gender) ANOVA procedures. Time effects were
tested by repeated-measures ANOVA. PF data were nonnormally
distributed and statistical analysis was therefore also preformed after
log transformation. Statistical results were similar and results obtained
with log-transformed data are reported. However, only nontransformed
values with arithmetic means and SD are shown. Because PF concen-
trations at 4 mo differed between study groups, the data also were
analyzed by ANCOVAwith PF at 4 mo as a covariate. Changes in PF and
Hb concentrations were calculated over 2-mo intervals during the
intervention. Pearson correlation coefficients were used to assess
relationships between variables. Values in the text are means 6 SD.
Results
Electrolytic iron vs. ferrous fumarate
Iron status. PF concentrations did not differ between infants
who were fed Cereal L and Cereal M except at 7.5 mo when PF
was lower in the Cereal L (electrolytic iron) than in the cereal M
(fumarate) group (P = 0.033) (Table 1). However, after
adjustment for the difference in PF at baseline (4 mo), the
difference at 7.5 mo was no longer significant (P = 0.06). In both
groups, concentrations showed the expected age-related
changes: PF decreased with increasing age (P , 0.001). Hb
and iron concentrations did not change and TfR initially
increased (P , 0.001) and stabilized after 5.5 mo. There were
no significant treatment-related differences in any of the other
iron status indices. In the per protocol analysis, there were
similarly no treatment-related differences. When changes in PF
and Hb were calculated for 2-mo intervals during the interven-
tion, there were no significant cereal-related differences, al-
though there were the expected age-related changes.
ID. Three infants had ID at the time of randomization at 4 mo,
all of whomwere born with low iron endowment (Table 2). Two
of them (1 in the Cereal L and 1 in the Cereal M group) were still
iron deficient at 5.5 mo. Two additional infants were iron
deficient at 5.5 mo [infant 10993 fed Cereal L and infant 10924
(not shown) fed Cereal M]. Thus, 4 infants (4.2% of those
randomized) had ID, but none had IDA. At 12 mo (3 mo after
cessation of the intervention), ID was present in 2 infants fed
Cereal L and in 6 infants fed Cereal M.
Cereal consumption. The mean estimated consumption of
study cereals exceeded the target amount of 15 g/d except during
the period from 4 to 5.5 mo, when it was less (Table 3).
However, the range of intakes was wide, with some infants
consuming only about one-half the target amount and others
consuming about twice the target amount. Corresponding
intakes of iron from study cereals similarly showed a wide
range. Overall, intake of cereal iron was 1.21 6 0.31 mg
kg21×d21 from Cereal L and 1.07 6 0.40 mg×kg21×d21 from
Cereal M, which did not differ (P = 0.10). The intake of cereal
iron during the 4- to 5.5-mo period was correlated with PF at
5.5 mo (r = 0.32; P = 0.003) and at 7.5 mo (r = 0.29; P = 0.015)
but not at 9 mo (r = 0.23; P = 0.065). Intakes of cereal iron
during the 5.5- to 7.5-mo and 7.5- to 9-mo periods were not
correlated with PF at 7.5 or 9 mo, respectively (data not shown).
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Growth. There were no differences between study groups in
weight or length attained, nor in weight or length gained.
Observed differences in gain were less than the detectable
differences of 2.31 g/d and 0.046 mm/d with 69 infants. There
were the expected gender-related differences, with boys being
heavier and longer than girls (P , 0.05).
Infants born with low iron endowment
A low birth iron endowment, defined as a PF concentration
, 55 mg/L (10th percentile value in the present dataset) at 2 mo
of age, was present in 11 infants, for whom individual data
are presented in Table 2. Two of these infants (10946, 10961)
were withdrawn by their parents, received supplemental iron,
and remained in good iron status. Three infants (10935, 10939,
10941) had IDA at 4 mo. They were not randomized and were
instead referred for treatment. IDA responded slowly to treat-
ment in infant 10935, but from 7.5 mo on the infant remained in
good iron status. In infant 10939, IDA resolved promptly with
treatment, but at 9 mo this infant had ID again; it is not clear
how long iron therapy was continued. No follow-up informa-
tion was obtained on infant 10941. The remaining 6 infants
born with low iron endowment were randomized at 4 mo, at
which time 3 (10913, 10933, 10937) had ID. A 4th infant
(10993) developed ID at 5.5 mo.
Thus, among infants born with low iron endowment, 3 had
IDA and 3 had ID without anemia by 4 mo of age, for a
prevalence of any early ID (IDA plus ID) of 54%. All 3 cases of
early IDA and 7 of 8 cases of early mild ID occurred in infants
born with low iron endowment. By contrast, among infants with
normal iron endowment, only 1 developed early ID without
anemia before 6 mo.
Entire study population. Among all infants enrolled (n = 111),
the prevalence of IDA, which occurred before 6 mo in each case,
was 2.7%. Twelve infants had ID without anemia on 1 or 2
occasions, for a prevalence of infants with ID of 10.8%. ID
occurred either early (5 infants) or late, i.e. at 12 mo (7 infants) or
early and late (1 infant). The number of infants with any ID (ID
and IDA) between 1 and 12mowas 15 for a prevalence of 13.5%.
TABLE 1 Iron status of 95 infants who were randomized to receive either Cereal L (electrolytic iron)
or Cereal M (ferrous fumarate) at 4 mo of age1
Cereal
Age
2 mo 4 mo 5.5 mo 7.5 mo 9 mo 12 mo
Infants,2 n L 50 50 43 37 36 36
M 45 45 40 34 33 33
PF,3 mg/L L 165 6 146 64 6 50 39 6 25 31 6 16 31 6 17 24 6 16
M 158 6 96 79 6 72 47 6 49 41 6 32* 37 6 29 23 6 17
Plasma sTfR, mg/L L 4.26 6 1.02 5.60 6 1.09 5.19 6 0.89 5.34 6 0.80 5.48 6 0.91 5.37 6 0.88
M 4.23 6 1.04 5.63 6 1.31 5.03 6 1.23 5.68 6 1.07 5.49 6 0.84 5.59 6 1.14
Ln[sTfR/ferritin] L 1.49 6 0.32 2.04 6 0.36 2.20 6 0.31 2.27 6 0.22 2.28 6 0.19 2.41 6 0.22
M 1.48 6 0.30 1.98 6 0.39 2.16 6 0.38 2.22 6 0.29 2.26 6 0.29 2.47 6 0.28
Plasma iron, mmol/L L 13.0 6 3.4 10.5 6 4.0 10.1 6 4.2 10.7 6 3.0 10.8 6 4.1 11.0 6 4.0
M 12.1 6 3.5 10.0 6 3.3 9.2 6 2.8 9.4 6 3.6 10.0 6 3.8 10.5 6 4.1
Blood Hb, g/L L 114 6 11 115 6 7 118 6 7 116 6 9 116 6 7 119 6 7
M 113 6 11 117 6 9 117 6 8 118 6 8 120 6 7 120 6 8
RDW,4 % L 14.2 6 1.0 12.5 6 0.9 13.0 6 1.3 14.1 6 1.2 14.3 6 1.4 13.7 6 1.0
M 14.2 6 1.1 12.4 6 1.0 13.0 6 1.3 13.9 6 1.4 13.9 6 1.2 13.6 6 1.0
MCV, fL L 92 6 4 82 6 4 78 6 4 78 6 5 79 6 4 79 6 4
M 92 6 4 82 6 4 79 6 4 79 6 3 80 6 3 80 6 4
1 Values are means 6 SD. *Different from Cereal L, P , 0.05.
2 Data for infants who left the study are included up to the point of departure.
3 Decreased with age, P = ,0.001.
4 RDW, relative distribution width of erythrocytes; MCV, mean corpuscular volume of erythrocytes.
TABLE 2 PF and blood Hb concentrations of infants who were
born with low iron endowment (PF # 55 mg/L at age




2 mo 4 mo 5.5 mo 7.5 mo 9 mo 12 mo
10913 L PF, mg/L 49 8 8 28 22 21
Hb, g/L 121 110 123 125 116 126
10933 L PF, mg/L 32 9 13 19 38 15
Hb, g/L 105 119 126 115 126 131
10937 M PF, mg/L 34 8 6 12 34 23
Hb, g/L 110 119 119 133 129 123
10991 M PF, mg/L 36 13
Hb, g/L 107 138
10993 L PF, mg/L 44 13 9 12 11 14
Hb, g/L 99 122 107 115 115 132
10998 M PF, mg/L 50 15 17 16 17 22
Hb, g/L 111 118 113 123
10935 NR1 PF, mg/L 29 5 10* 16* 24*
Hb, g/L 105 101 100* 111* 112*
10939 NR PF, mg/L 55 4 15* 18* 5* 17*
Hb, g/L 100 105 114* 113* 109* 108*
10941 NR PF, mg/L 39 2
Hb, g/L 102 100
10946 NR PF, mg/L 27 12 12* 14* 41*
Hb, g/L 142 100 111* 125* 121* 113*
10961 NR PF, mg/L 40 21 18* 21* 20* 60*
Hb, g/L 108 122 126* 125* 117* 132*
1 NR, Not randomized. *Values obtained during and after Fe treatment.
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PF. At 2 mo of age, the PF concentration was 1516 96 mg/L (n =
106) with a range from 27 to 432 mg/L. The 5th, 10th, 50th,
90th, and 95th percentiles were 39, 55, 132, 259, and 318 mg/L,
respectively. At 4 mo of age, PF was 686 61 mg/L (n = 97) with a
range from 2 to 379 mg/L. The 5th, 10th, 50th, 90th, and 95th
percentiles were 8, 15, 54, 142, and 187 mg/L, respectively. PF
was significantly higher in girls than in boys at 2, 4, and 5.5 mo
but not at later ages (data not shown).
PF concentrations showed strong tracking, as indicated by
significant correlation coefficients that decreased somewhat with
increasing length of age intervals but remained significant for
intervals as long as 8 mo (Table 4).
Discussion
This study involved healthy infants who were exclusively breast-
fed at the time of enrollment at 2 mo and at the time of
randomization at 4 mo. Thereafter, they began to consume
various complementary foods but did not receive formula. The
study cereals were provided from 4 to 9 mo and were consumed
by all infants, with mean consumption approximating the
intended amount (15 g/d). Iron provided by study cereals was,
after the initial 2 mo, somewhat more than 1 mg×kg21×d21.
Infants who developed IDA in the first month of life were
excluded from the study but were followed.
Contrary to our hypothesis, the study produced no evidence
that ferrous fumarate is a more efficacious fortificant of infant
cereal than electrolytic iron in maintaining iron status and
preventing ID in breast-fed infants. With either source of iron,
the prevalence of ID was 4.2% and the prevalence of IDA was
0%. It must be kept in mind that in this study, parents were
asked to feed the cereals every day and in relatively large
amounts. The suggested daily amounts of cereal were intended
to ensure intakes of iron that the investigators deemed necessary
to maintain good iron status. The amounts consumed were
similar to those reported by Walter et al. (9). There were no
difficulties reported in infants consuming the suggested amounts
and actual intakes varied over a wide range. But it appears likely
that free-living infants received lesser amounts of cereals and
may not have received cereal every day. Although the prevalence
of ID (4.2%) was slightly higher than assumed in our power
calculation, ID was in all cases mild and transient.
In contrast, in our earlier study (16) in which the parents of
control infants freely chose complementary foods, 14.3% of
infants developed ID between 4 and 9 mo of age, including 2
infants with IDA. Not all infants in that study consumed cereal,
but quite a few consumed some formula. In comparison, infants
in the present study consumed no formula but still had much less
ID, suggesting that the regular consumption of these iron-
fortified cereals offered relative protection from ID.
Because infants with the worst iron status, i.e. 3 infants with
early IDA, were excluded from the study proper, it remains
unknownwhether the cereals would have been able to normalize
iron status in these infants.
That electrolytic iron appeared to be equally effective as
ferrous fumarate came somewhat as a surprise, because the
literature led us to expect that the fumerate form would
outperform electrolytic iron. Several explanations appear pos-
sible. One is that the cereals provided a surfeit of iron, so that
even in the presence of a difference in bioavailability each
provided sufficient absorbed iron. Another explanation is that
enough ascorbic acid, a known enhancer of iron availability
(34), may have survived the cooking and drying process and may
have enhanced iron availability to the point where any difference
between the 2 fortificants was eliminated. Because the currently
marketed dry infant cereals in the US no longer include ascorbic
acid as an ingredient, the present results should not be
extrapolated to current U.S. infant feeding practice.
The study produced further evidence that infants who are
born with a low iron endowment are at increased risk of ID, in
particular during the first 4 mo of life. A full 54% of infants born
with low storage iron developed ID in the first 4 mo of life,
including all 3 who developed IDA. We (15,16) and others (35–
37) have previously reported that infants with a low birth iron
endowment are at increased risk of ID and IDA early in life. This
increased risk during the first 6 mo of life occurs at a time during
which ID has traditionally not been expected.
The study had some limitations. Because the feeding of
supplemental formula was not permitted, infants depended
exclusively on complementary foods as a source of iron. Among
free-living breast-fed infants, supplemental formula is often fed
and provides a readily available source of iron (ferrous sulfate).
Infants with manifest IDA were excluded from the study.
Therefore, nothing can be said about the efficacy of iron-
fortified infant cereals in preventing or correcting IDA. How-
ever, because IDA had developed by 4 mo, the age at which
complementary foods are beginning to be introduced, iron-
fortified cereals cannot be expected to prevent early IDA.
Because the study had no placebo group, inferences regarding
the overall effectiveness of the cereals in preventing ID could
only be drawn from comparisons with historical data.
In conclusion, the results suggest that the regular consumption
of iron-fortified infant cereals can afford breast-fed infants at least
TABLE 3 Daily consumption of cereals L or M and of cereal iron
during successive 2-mo periods by infants1
Cereal
Age interval
4–5.5 mo 5.5–7.5 mo 7.5–9 mo
Infants, n L 47 40 35
M 40 34 33
Cereal,2 gd21 L 11.3 6 4.4 19.4 6 7.4 23.6 6 8.4
(5.2–27.8) (3.4–43.1) (5.3–39.9)
M 11.7 6 5.2 19.1 6 7.3 19.8 6 9.3
(2.9–25.1) (9.0–33.3) (2.4–39.0)
Cereal iron,2 mgd21 L 6.1 6 2.4 11.6 6 7.0 13.9 6 7.5
M 6.1 6 2.7 10.0 6 7.3 10.3 6 4.8
Cereal iron,2 mgkg21d21 L 0.88 6 0.34 1.39 6 0.56 1.54 6 0.54
M 0.86 6 0.39 1.28 6 0.50 1.19 6 0.54
1 Values are mean 6 SD (range).
2 Increased with age, P , 0.001.
TABLE 4 Pearson correlations between PF concentrations of
infants who consumed cereal L or M at different ages
Age 4 mo 5.5 mo 7.5 mo 9 mo 12 mo
r1
2 mo 0.91 0.82 0.72 0.67 0.54
4 mo 0.87 0.84 0.82 0.67
5.5 mo 0.82 0.75 0.61
7.5 mo 0.82 0.64
9 mo 0.74
1 All P , 0.05.
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partial protection against ID. The 2 dry infant cereals fortified
with electrolytic iron (A-131) and ferrous fumarate and contain-
ing ascorbic acid appeared to be equally efficacious inmaintaining
iron status and protecting breast-fed infants against ID.
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